Search - Université de Rennes Access content directly

Filter your results

17 Results
authFullName_s : S. Vukusic

Assessing the cumulative effects of disease-modifying therapies on the current risk of irreversible disability in patients with relapsing-remitting multiple sclerosis

F. Rollot , Romain Casey , Marc Debouverie , Gilles Edan , S. Wiertlewski et al.
Multiple Sclerosis Journal, 2018, 24, pp.344-345
Journal articles hal-01935071v1

Immunization and multiple sclerosis: Recommendations from the French Multiple Sclerosis Society

C. Lebrun , S. Vukusic , V. Abadie , C. Achour , F. Ader et al.
Revue Neurologique, 2019, 175 (6), pp.341-357. ⟨10.1016/j.neurol.2019.04.001⟩
Journal articles hal-02546158v1

Understanding heterogeneity in comparative effectiveness studies of natalizumab and fingolimod in multiple sclerosis: effect of analytical methodology

M. Lefort , S. Shannin , Jørgen Vitting Andersen , S. Vukusic , N. J. Koch-Henriksen et al.
European Journal of Neurology, 2020, 27, pp.342-342
Journal articles hal-02887182v1
Image document

Impact of methodological choices in comparative effectiveness studies: application in natalizumab versus fingolimod comparison among patients with multiple sclerosis

M. Lefort , S. Sharmin , J. Andersen , S. Vukusic , R. Casey et al.
BMC Medical Research Methodology, 2022, 22 (1), pp.155. ⟨10.1186/s12874-022-01623-8⟩
Journal articles hal-03690493v1

Comparative efficacyof fingolimod versus natalizumab in multiple sclerosis: a prospective multicenter observational study

D. A. Laplaud , L. Barbin , Chloé Rousseau , N. Jousset , Romain Casey et al.
Multiple Sclerosis Journal, 2015, 31st Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS), Barcelona, SPAIN, OCT 07-10, 2015, 21 (11), pp.62--63
Journal articles hal-01259392v1

Excess mortality in patients with relapsing-onset multiple sclerosis depends on age rather than disease duration: new insights from an innovative flexible model applied on French OFSEP data ('Observatoire Francais de la Sclerose en Plaques')

F. Rollot , M. Fauvernier , Z. Uhry , S. Vukusic , N. Bossard et al.
Multiple Sclerosis Journal, 2019, 25, pp.103-104
Journal articles hal-02363491v1

Disease-modifying therapies use in primary progressive multiple sclerosis patients in France data from the OFSEP cohort over the 1996-2017 period

Emmanuelle Leray , F. Rollot , Romain Casey , J. de Seze , D. A. Laplaud et al.
Multiple Sclerosis Journal, 2017, 23, pp.659-660. ⟨10.26226/morressier.59a3edacd462b8028d8957a8⟩
Journal articles hal-01716028v1

High and low efficacy therapy in secondary progressive multiple sclerosis after accounting for therapeutic lag

I. Roos , Emmanuelle Leray , Romain Casey , D. Horakova , E. Kubala Havrdova et al.
Multiple Sclerosis Journal, 2020, 26 (3_SUPPL), pp.534-535
Journal articles hal-03127244v1

Urinary tract infections and multiple sclerosis: Recommendations from the French Multiple Sclerosis Society

C. Donzé , C. Papeix , C. Lebrun-Frenay , N. Collongues , M. de Seze et al.
Revue Neurologique, 2020, 176 (10), pp.804-822. ⟨10.1016/j.neurol.2020.02.011⟩
Journal articles hal-03339824v1

Disease-modifying therapies use in relapsing-onset multiple sclerosis patients in real-life settings in France data from the OFSEP database over the period 1996-2017

Emmanuelle Leray , F. Rollot , Romain Casey , J. de Seze , D. A. Laplaud et al.
Multiple Sclerosis Journal, 2017, 23, pp.709-709. ⟨10.26226/morressier.59a3e8b4d462b8028d894343⟩
Journal articles hal-01716027v1

Clinical course and therapeutic management of spms in france: a retrospective real world multicentric observational study (odyssep study)

Emmanuelle Leray , A. Bastien , K. Rerat , A. Cognee-Chauvin , E. Raponi et al.
Multiple Sclerosis Journal, 2020, 26 (3_SUPPL), pp.524-525
Journal articles hal-03105858v1

Quelle utilisation des traitements de fond chez des patients ayant une sclérose en plaques rémittente en France sur la période 1990–2017 ? Étude des données de l’Observatoire français de la SEP

Emmanuelle Leray , Jonathan Roux , F. Rollot , Romain Casey , J. de Seze et al.
Epidemiology and Public Health = Revue d'Epidémiologie et de Santé Publique, 2018, 66, pp.S227. ⟨10.1016/j.respe.2018.04.033⟩
Journal articles hal-02921604v1

Baseline characteristics of the first patients included in the OFSEP high definition cohort and relationship between quality of life and patients' characteristics

Romain Casey , I. El-Bahi , F. Rollot , Francis Guillemin , D. -A. Laplaud et al.
Multiple Sclerosis Journal, 2019, 25 (2_suppl), pp.196-196. ⟨10.1177/1352458519868078⟩
Journal articles hal-02363488v1

The OFSEP high definition cohort to prognosticate the evolution of multiple sclerosis at clinical key steps of the disease

Romain Casey , Francis Guillemin , D. A. Laplaud , Emmanuelle Leray , J. Epstein et al.
Multiple Sclerosis Journal, 2018, 24, pp.772-772. ⟨10.26226/morressier.5b719e445aff74008ae4cb10⟩
Journal articles hal-01939727v1

Improving the decision to switch from first to second-line therapy in MS: a dynamic scoring system

C. Sabathe , Romain Casey , S. Vukusic , Emmanuelle Leray , G. Mathey et al.
Multiple Sclerosis Journal, 2021, ECTRIMS 2021 Committees, 27 (Suppl 2), pp.22-24. ⟨10.1177/13524585211044647⟩
Journal articles hal-03464227v1

MD1003 (high doses of biotin) in progressive multiple sclerosis: subgroup analyses of the MS-SPI trial

Ayman Tourbah , Christine Lebrun-Frenay , Gilles Edan , M. Clanet , C. Papex et al.
Multiple Sclerosis Journal, 2015, 31st Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS), Barcelona, SPAIN, OCT 07-10, 2015, 21 (11), pp.785
Journal articles hal-01259396v1

Neuraxial analgesia is not associated with an increased risk of post-partum relapses in MS

Caroline Lavie , Fabien Rollot , Françoise Durand-Dubief , Romain Marignier , Iuliana Ionescu et al.
Multiple Sclerosis Journal, 2019, 25 (4), pp.591-600. ⟨10.1177/1352458518763080⟩
Journal articles hal-02158735v1